24th Oct 2016 16:00
24 October 2016
Grant of Share Options
Clinigen Group plc (the "Company") (AIM: CLIN), announces that, on 21 October 2016, the following directors and PDMR's were granted share options over a total of 328,053 ordinary shares of 0.1 pence each ("Ordinary Shares") as listed below, granted under the Clinigen Group Long Term Incentive Plan 2015. The options are nil cost options intended to vest on 21 October 2019 subject to the achievement of certain performance criteria.
Director/PDMR | Number of share options granted | Total number of share options now held | Total number of ordinary shares now held | Total number of ordinary shares (excluding share options) as % issued share capital |
Shaun Chilton | 159,893 | 239,886 | 412,943 | 0.36% |
Martin Abell | 36,642 | 163,660 | 19,404 | 0.02% |
Simon Estcourt | 26,632 | 123,843 | 7,000 | 0.01% |
Steve Glass | 27,315 | 138,695 | nil | nil |
Debra Ainge | 23,317 | 42,137 | 8,968 | 0.01% |
Johann Willemse | 54,254 | 54,254 | nil | nil |
-Ends-
Contact details
Clinigen Group plc | Tel: +44 (0) 1283 495010 |
Shaun Chilton, Group Chief Executive Officer-designate | |
Martin Abell, Group Chief Financial Officer | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) James Black / Tom Ballard (Corporate Broking) | |
Peel Hunt LLP | Tel: +44 (0) 20 7418 8900 |
James Steel / Dr Christopher Golden | |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Adrian Duffield / Melanie Toyne-Sewell / Jayne Crook | Email: [email protected] |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.
The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.
The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.
For more information, please visit www.clinigengroup.com
Related Shares:
CLIN.L